Literature DB >> 34088867

Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies.

Suowen Xu1, Iqra Ilyas2, Peter J Little2, Hong Li2, Danielle Kamato2, Xueying Zheng2, Sihui Luo2, Zhuoming Li2, Peiqing Liu2, Jihong Han2, Ian C Harding2, Eno E Ebong2, Scott J Cameron2, Alastair G Stewart2, Jianping Weng3.   

Abstract

The endothelium, a cellular monolayer lining the blood vessel wall, plays a critical role in maintaining multiorgan health and homeostasis. Endothelial functions in health include dynamic maintenance of vascular tone, angiogenesis, hemostasis, and the provision of an antioxidant, anti-inflammatory, and antithrombotic interface. Dysfunction of the vascular endothelium presents with impaired endothelium-dependent vasodilation, heightened oxidative stress, chronic inflammation, leukocyte adhesion and hyperpermeability, and endothelial cell senescence. Recent studies have implicated altered endothelial cell metabolism and endothelial-to-mesenchymal transition as new features of endothelial dysfunction. Endothelial dysfunction is regarded as a hallmark of many diverse human panvascular diseases, including atherosclerosis, hypertension, and diabetes. Endothelial dysfunction has also been implicated in severe coronavirus disease 2019. Many clinically used pharmacotherapies, ranging from traditional lipid-lowering drugs, antihypertensive drugs, and antidiabetic drugs to proprotein convertase subtilisin/kexin type 9 inhibitors and interleukin 1β monoclonal antibodies, counter endothelial dysfunction as part of their clinical benefits. The regulation of endothelial dysfunction by noncoding RNAs has provided novel insights into these newly described regulators of endothelial dysfunction, thus yielding potential new therapeutic approaches. Altogether, a better understanding of the versatile (dys)functions of endothelial cells will not only deepen our comprehension of human diseases but also accelerate effective therapeutic drug discovery. In this review, we provide a timely overview of the multiple layers of endothelial function, describe the consequences and mechanisms of endothelial dysfunction, and identify pathways to effective targeted therapies. SIGNIFICANCE STATEMENT: The endothelium was initially considered to be a semipermeable biomechanical barrier and gatekeeper of vascular health. In recent decades, a deepened understanding of the biological functions of the endothelium has led to its recognition as a ubiquitous tissue regulating vascular tone, cell behavior, innate immunity, cell-cell interactions, and cell metabolism in the vessel wall. Endothelial dysfunction is the hallmark of cardiovascular, metabolic, and emerging infectious diseases. Pharmacotherapies targeting endothelial dysfunction have potential for treatment of cardiovascular and many other diseases.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Year:  2021        PMID: 34088867     DOI: 10.1124/pharmrev.120.000096

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  56 in total

Review 1.  Purinergic receptors mediate endothelial dysfunction and participate in atherosclerosis.

Authors:  Xian-Ming Wu; Ning Zhang; Jiang-Shan Li; Zhi-Hong Yang; Xiao-Lou Huang; Xiao-Fang Yang
Journal:  Purinergic Signal       Date:  2022-01-03       Impact factor: 3.765

Review 2.  Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.

Authors:  Yajun Duan; Ke Gong; Suowen Xu; Feng Zhang; Xianshe Meng; Jihong Han
Journal:  Signal Transduct Target Ther       Date:  2022-08-02

Review 3.  Molecular Mechanisms Underlying Pathological and Therapeutic Roles of Pericytes in Atherosclerosis.

Authors:  Siarhei A Dabravolski; Alexander M Markin; Elena R Andreeva; Ilya I Eremin; Alexander N Orekhov; Alexandra A Melnichenko
Journal:  Int J Mol Sci       Date:  2022-10-01       Impact factor: 6.208

Review 4.  Sex differences and related estrogenic effects in heart failure with preserved ejection fraction.

Authors:  Deng Shuaishuai; Lin Jingyi; Zhao Zhiqiang; Fan Guanwei
Journal:  Heart Fail Rev       Date:  2022-10-03       Impact factor: 4.654

Review 5.  The role of ferroptosis in endothelial cell dysfunction.

Authors:  Wei Yuan; Hao Xia; Yao Xu; Chong Xu; Nan Chen; Chen Shao; Zhiyin Dai; Rui Chen; Aibin Tao
Journal:  Cell Cycle       Date:  2022-06-14       Impact factor: 5.173

Review 6.  Endothelial Dysfunction and Arterial Stiffness in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Authors:  Hao Wu; Meihua Xu; Hong Hao; Michael A Hill; Canxia Xu; Zhenguo Liu
Journal:  J Clin Med       Date:  2022-06-02       Impact factor: 4.964

Review 7.  Unexpected Role of MPO-Oxidized LDLs in Atherosclerosis: In between Inflammation and Its Resolution.

Authors:  Cecilia Tangeten; Karim Zouaoui Boudjeltia; Cedric Delporte; Pierre Van Antwerpen; Keziah Korpak
Journal:  Antioxidants (Basel)       Date:  2022-04-28

8.  MEK1/2 inhibitor inhibits neointima formation by activating miR-126-3p/ C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C motif chemokine receptor 4 (CXCR4) axis.

Authors:  Yali Yan; Mengmeng Zhu; Jialing Ma; Xiaoyu He; Xiaoxiao Yang; Hongmei Xu; Meixiu Jiang; Shuang Zhang; Yajun Duan; Jihong Han; Yuanli Chen
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

9.  Identification of hub genes and transcription factors in patients with rheumatoid arthritis complicated with atherosclerosis.

Authors:  Lu Xiao; Zhou Yang; Shudian Lin
Journal:  Sci Rep       Date:  2022-03-18       Impact factor: 4.379

10.  The zinc finger transcription factor, KLF2, protects against COVID-19 associated endothelial dysfunction.

Authors:  Suowen Xu; Yujie Liu; Yu Ding; Sihui Luo; Xueying Zheng; Xiumei Wu; Zhenghong Liu; Iqra Ilyas; Suyu Chen; Shuxin Han; Peter J Little; Mukesh K Jain; Jianping Weng
Journal:  Signal Transduct Target Ther       Date:  2021-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.